FOLFIRINOX相关论文
目的:收集并分析FOLFIRINOX（伊立替康、奥沙利铂、氟尿嘧啶、亚叶酸钙）方案和白蛋白结合型紫杉醇联合吉西他滨（NAB-P+GEM）方案治疗进展......
目的:MUC1是调控胰腺癌代谢的重要蛋白。甘露糖被报道具有抑制肿瘤细胞糖代谢的作用。本研究为了探索MUC1调控胰腺癌代谢的机制,以......
学位
通过比较真实世界接受FOLFIRINOX(亚叶酸+奥沙利铂+伊立替康+氟尿嘧啶)或GN(吉西他滨+白蛋白结合型紫杉醇)方案治疗的晚期胰腺癌患......
目的:本研究旨在通过相关文献研究的荟萃分析,比较FOLFIRINO X和白蛋白结合型紫杉醇联合吉西他滨方案在胰腺癌治疗方面的特点,主要......
学位
Enhanced glucose metabolism is one of the hallmarks of pancreatic cancer.MUC 1,a transmembrane protein,is a global regul......
目的:MUC1是调控胰腺癌代谢的重要蛋白。甘露糖被报道具有抑制肿瘤细胞糖代谢的作用。本研究为了探索MUC1调控胰腺癌代谢的机制,以......
学位
1 文献来源rnChiorean EG,Cheung WY,Giordano G,et al. Real-world comparative effectiveness of nab-Paclitaxel plus Gemcitab......
Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to
Background: Stent insertion for biliary decompression to relieve jaundice and subsequent biliary infec-tion is necessary......
目的:探讨局部进展期胰腺癌（LAPC）患者行FOLFIRINOX（5-氟尿嘧啶、奥沙利铂、伊立替康、亚叶酸钙）为基础的新辅助化疗后的手术切除率及......
AIM To study the tolerance and the efficiency of FOLFIRINOX in elderly patients diagnosed with colorectal or pancreatic ......
Pancreatic cancer is an extremely aggressive disease; although progress has been made in the last few years, the prognos......
Pancreatic cancer is one of the leading causes of cancer death worldwide.Adjuvant chemotherapy has been developed based ......
Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line
AIM To directly compare the efficacy and toxicity of standarddose FOLFIRINOX(sFOLFIRINOX)and modified-dose FOLFIRINOX(mF......
Due to extremely poor prognosis, pancreatic cancer（PDAC） represents the fourth leading cause of cancerrelateddeath in West......
Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to
Background:Stent insertion for biliary decompression to relieve jaundice and subsequent biliary infection is necessary f......
FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A po
BACKGROUND FOLFIRINOX regimen is the first-line reference chemotherapy(L1)in advanced pancreatic ductal adenocarcinoma(a......
目的应用Meta分析的方法系统评估局部进展期胰腺癌(交界性可切除胰腺癌)术前使用FOLFIRINOX新辅助化疗方案的疗效,根据结果探讨该......
学位
BACKGROUND Gemcitabine plus nab-paclitaxel(GA)and modified FOLFIRINOX(FFX)have been widely used as standard first-line t......
Patients with metastasized carcinoma of the pancreashave a very poor prognosis, and long-term survivalcannot be expected......
Pancreatic cancer(PDAC) is an aggressive and chemoresistant disease, representing the fourth cause of cancer related dea......
背景与目的奥沙利铂(oxaliplatin)、伊立替康(irinotecan)、5-氟尿嘧啶(5-fluorouracil和l-醛氢叶酸(l-leucovorin)联合用药(即FOL......
FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer:Single-center
BACKGROUND FOLFIRINOX and gemcitabine plus nab-paclitaxel(Gem+nabPTX)were recently introduced for metastatic pancreatic ......
目的评价以5-氟尿嘧啶、亚叶酸钙、伊立替康和奥沙利铂(FOLFIRINOX方案)作为一线方案治疗潜在可切除(BRPC)和局部不可切除胰腺癌(L......
1文献来源Chiorean EG,Cheung WY,Giordano G,et al.Real world comparative effectiveness of nab Paclitaxel plus Gemcitabine ......
摘要目的探讨可疑可切除性(BR)及局部晚期(LA)胰腺癌二次手术后FOLFIRINOX(5-氟尿嘧啶/亚叶酸钙/伊立替康/奥沙利铂)新辅助化疗后C......
AIM To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refracto......
总结23例接受FOLFIRINOX方案化疗的胰腺癌患者护理,密切观察化疗后出现的不良反应(消化道反应、骨髓移植、神经毒性反应、延时性腹......
期刊
目的:评估改良FOLFIRINOX方案治疗进展期胰腺癌的临床疗效和安全性。方法:本研究共纳入2014年4月至2016年12月在本中心接受改良FOL......
学位
